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Porcine transforming growth factor ! and 2 (pTGF-fll and -//2) and milk growth factor (MGF) at 1 ng/ml significantly 
inhibited the proliferation of human lymphocytes induced by anti-CD3 antibodies. In contrast, the anti-CD3-mediated 
increase of intracellular Ca 2+ and the activation and translocation ofprotein kinase C were not affected by the transform- 
ing growth factors. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Among the earliest events detectable in human 
lymphocyte stimulation (review [ 1]) are an increase 
in intracellular Ca 2+ ([Ca2+]i) and the activation 
and translocation of a Ca2+/phospholipid-depen - 
dent protein kinase (protein kinase C, PK-C) both 
of which can be induced by anti-CD3 antibodies 
[2,3]. The transforming growth factors/~ (TGF-/Y) 
(review [4]) are thought to play an important role in 
the control of cellular proliferation and have been 
shown to inhibit lymphocyte stimulation. We in- 
vestigated whether TGF-/~I, -/Y2 and milk growth 
factor, a bovine TGF-/~2-1ike molecule, interfered 
with the increase of [Ca2+]i and the activation of 
PK-C in human anti-CD3-stimulated lymphocytes. 
2.1. Chemicals 
Medium HB 102 (DuPont, Dreieich) was supplemented with 
2 mM glutamine, 100 U/100/~g/ml penicillin/streptomycin, 10 
mM Hepes, 1 mM pyruvate and the HB 102 serum supplement. 
The mAbs BMA 030 and BMA 031, which recognize the human 
CD3 structure or the human T cell receptor (TCR) respectively, 
were obtained from Behringwerke (Marburg). Porcine trans- 
forming growth factor b'l and/Y2 (pTGF-~'I- and -/T2) were ob- 
tained from R&D Systems (Minneapolis, MN). Milk growth fac- 
tor (MGF) was kindly donated by Ciba-Geigy and is a 25 kDa 
dimer from bovine milk purified to homogeneity, which 
together with EGF induces anchorage-independent growth in 
49F fibroblasts and is indistinguishable from bovine TGF-b'2. 
(Cox, D. et al., in preparation). 
2.2. Cell culture 
PBL from huffy coats were obtained from the local transfu- 
sion centre and washed twice. 
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2.3. 13H]Thymidine i corporation 
PBL (1 x 106/ml) were cultured in HB 102 in 96-well 
microtiter plates in 4-fold replicates and stimulated with 20 
ng/ml BMA 030. TGF-~'I, -/T2 or MGF (10-0.001 ng/ml) was 
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Table 1 
Effect of  pTGF-~I, pTGF-ff2 and MGF on anti-CD3-induced [3H]thymidine 
incorporation in human lymphocytes 
Experiment 
1 2 3 
Q 450 a ± 73 241 + 141 234 ± 32 
+ BMA030 14140 ± 825 53778 _+ 869 36589 ± 2812 
pTGF-,6'I pTGF-,6'2 MGF 
+ 5 ng/ml 9578 + 945 31255 + 2453 23 905 :t: 1 843 b 
+ lng /ml  7204_+ 445 37 735 ± 2990 23 702 _ 1049 
+ 0.1 ng/ml 11093 + 445 48746 _ 835 34163 _ 1555 
+ 0.01 ng/ml 13914 + 899 48589 _ 2697 37804 ± 2039 
+ 0.001ng/ml  14287 ± 1049 53 195 ± 3009 40181 + 1132 
a Values: cpm 
b 10 ng/ml MGF 
Human PBL (3 different donors) were stimulated for 72 h with 20 ng/ml of the anti-CD3 
mAb BMA 030 with or without pTGF-/5'I, -/32 or MGF. [3H]Thymidine was added for the 
last 4 h of  culture 
added at the start of the culture. Cultures were pulsed with 
[3H]thymidine (0.5/~Ci/well, spec. act. 5 Ci/mmol) during the 
last 4 h of a 72 h culture period. 
2.4. Measurement ofPK-C translocation 
Cells (5 × 106/ml) were cultured in RPMI 1640 (sup- 
plemented with 20 mM Hepes and 5 mg/ml  defatted bovine 
serum albumin) at 37°C with or without 1 ng/ml  TGF-~'I or -/32 
for at least 45 min before adding 20 ng/ml BMA 030. 15 rain 
after the addition of the mAb the cells were spun down and the 
membrane-bound and cytosolic fractions of PK-C were 
prepared as described [3]. 
2.5. Measurement ofcytosolic free calcium levels [Ca2+]i 
Cells (1 × 106/ml) were preincubated for at least 45 min with 
1 ng/ml  pTGF-~I or -/72. [Ca2+]i was measured with fura-2 [5]. 
During all subsequent s eps of  washing, loading with fura-2 and 
actual measurement, the concentration of TGF-~' was kept con- 
stant at l ng/ml.  Cells were washed twice with PBS and in- 
cubated at a density of  l06 cells/ml at 37°C for 30 rain in the 
presence of  5/zM fura-2/AM. The labelled cells were washed in 
PBS and resuspended in PBS supplemented with 1 mM CaCl2, 
1 mM MgCl2 and 1 g/1 glucose. Aliquots of 1.5 × 106 cells in 
1.5 ml were placed in a fluorometer (Aminco SPF-500) in 
magnetically stirred cuvettes, the temperature being maintained 
Table 2 
Effect of TGFo/31, TGF-ff2 and MGF on anti-CD3-mediated activation of protein kinase 
C in human PBL 
Expt 1 Expt 2 Expt 3 
Cytosol Membrane Cytosol Membrane Cytosol Membrane 
1488 397 1012 225 1143 161 
TGF/  
MGF 1532 313 1128 257 1178 205 
BMA 030 682 933 705 726 524 630 
BMA 030 
+ TGF/  
MGF 557 940 762 807 481 617 
Human PBL were stimulated with 20 ng/ml  of the anti-CD3 mAb BMA 030 with or 
without 1 ng/ml pTGF-•I (expt 1), in pTGF-/5'2 (expt 2) or MGF (expt 3). Cytosolic and 
membrane bound PK-C activity was determined as in [3]. PBL used for expts l and 2 are 
the same as in expts 1 and 2 in table 1. Values expressed as pmol 32p/mg protein per min 
290  
Volume 249, number 2 FEBS LETTERS June 1989 
Cont ro l  
+ pTGF - 91 
1 ng/ml 
, pTGF-  [32 
1 ng/rnl 
BMA 030 
150 ng / m l 
1 mia  
BMA 031 
3 #g / ml 
1~4e .M] 
Fig.1. Human PBL were stimulated with the anti-CD3 mAb 
BMA 030 or the anti-TCR mAb BMA 031 in the absence or 
presence of 1 ng/ml pTGF-~'I or -Z~r2. [Ca2÷]i was determined 
with fura-2. Boxed numbers, [Ca2+]i after stimulation; unboxed 
numbers, basal [Ca2+]i. Arrow: addition of antibody. 
at 37°C. The fura-2 fluorescence was monitored continuously 
using monochromator settings of 339 nm (excitation) and 492 
nm (emission). The [Ca2+]i levels were calculated using the 
general formula [Ca2+]i = Kd (F-Fmin)/(Fmax-F); where Kd is 
the dissociation constant for Ca 2+ binding to the indicator and 
F is  arbitrary fluorescence units. For fura-2 a value ofKa = 224 
nM was used [6]. Fmax was determined by lysing cells with 0.01% 
Triton X-100. Fmin was evaluated by adjusting the pH of the 
lysed cells to 10.5 with 60 nM Tris and addition of 7.5 mM 
EGTA. 
3. RESULTS 
[3H]Thymidine incorporation of human PBL in- 
duced by the anti-CD3 mAb BMA 030 was decreas- 
ed by pTGF-~'I, -/?2 and MGF (table 1). The inhibi- 
tion of [3H]thymidine incorporation was not com- 
plete and the maximum decrease was obtained at 1 
ng/ml. The dose-response curves were similar. We 
have obtained equivalent results using the anti- 
CD3 mAb Lau-T3 (Stoeck, M. et al., submitted). 
The effects of pTGF-/5'I, -/?2 and MGF on the 
translocation of PK-C mediated by mAb 030 are 
shown in table 2. Whereas BMA 030 increased the 
membrane-bound fraction and decreased the 
cytosolic fraction of PKC, pTGF-~I, -/Y2 and MGF 
at 1 ng/ml neither influenced the translocation 
mediated by BMA 030 nor translocated PKC by 
themselves. Fig. 1 shows the effect of pTGF-fll and 
-if2 on the increase of [Ca2+]i nduced by mAb 
BMA 030. Neither pTGF-~'I nor -f12 inhibited the 
increase of [Ca2+]i induced by either antibody. 
Similar results were obtained using the mAb BMA 
031 which recognizes the human TCR. 
4. DISCUSSION 
Our data show that pTGF-~'I, pTGF-/~r2 and 
MGF decrease [3H]thymidine incorporation i to 
anti-CD3-stimulated human lymphocytes without 
interfering with the increase of intracellular Ca 2÷ 
and the translocation of PK-C. This suggests that 
the transforming growth factors/~ exert their in- 
hibitory function somewhere 'downstream' of the 
first events of cell activation. This concept is also 
supported by the data of Siepl et al. [7] and from 
our laboratory (Stoeck, M. et al., submitted) which 
show that TGF-/~ interferes with lymphocyte ac- 
tivation induced by a Ca 2+ ionophore and a phor- 
bol ester, a combination which circumvents the 
respective arly events in lymphocyte activation 
[8]. In addition, IL-2-driven proliferation, which 
has been shown to be independent of PK-C 
translocation [9], is inhibited by TGF-/~ [4]. Fur- 
thermore, Chambard and Pouyss6gur [10] have 
demonstrated that TGF-/5' inhibits the growth of 
fibroblasts without interfering with a series of 'ear- 
ly events'. In conclusion, TGF-# appears not to in- 
hibit cell proliferation by interference with an event 
at the beginning of the activation cascade. 
Besides their inhibitory and antiproliferative ef-
fects the transforming growth factors/~ also have 
stimulatory properties in several systems [4]. Here, 
it is of interest hat Muldoon et al. [11,12] have 
reported that in Rat-1 cells TGF-/? increases the IP3 
and IP4 levels and enhances the EGF-mediated in- 
crease in [Ca2+]i. Furthermore Markovac and 
Goldstein [13] have shown that TGF-/Y activates 
protein PK-C in microvessels i olated from im- 
mature rat brain and suggested a role for TGF-fl in 
brain microvascular differentiation. Thus, the ef- 
fects of TGF-/~ on the early events could be depen- 
dent on the cell type and on its differentiation state. 
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